Dr. Tommy Wood

speaker

1,133 appearances 1 recordings 1 series first heard Jul 2026 last heard 20 Jul

Dr. Tommy Wood’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

Huberman Lab · Accelerate Learning & Increase Cognitive Capacity | Dr. Tommy Wood · 20 Jul 2026 podcast

And they showed that rates of other diseases weren't that different, rates of uptake of other healthcare and other vaccines wasn't that different, but there was a big shift in the uptake of the shingles vaccine.

And so what they essentially consistently showed across all those different populations was that those who got the shingles vaccine or were eligible to have the shingles vaccine, depending on whether they had access to the data on whether people got it or not, had a decreased risk of dementia.

And that was consistently seen across those three groups.

All those three trials used an older version of the shingles vaccine called Zostavax, which was a live attenuated vaccine.

There's now a newer version called Shingrix, which is a recombinant vaccine.

And there was a study done in the US that compared people who switched from... There was a similar switch from Zostavax to Shingrix and saw that Shingrix was associated with a lower risk of dementia compared to Zostavax, although both were associated with a lower risk than none.

When you look at some of these trials or studies, because they're not trials, people have made a very fair comment, which is that when you look at the trajectory of dementia over time, you look at something called a Kaplan-Meier curve.

So it's like a survival curve.

So like every time somebody gets a case of dementia, like the line goes up.

You look at the trajectory of the two lines, those who got the vaccine or not, they diverge very early, which says that, oh, it only takes a couple of months to see this difference in dementia risk, which you wouldn't really expect based on the natural course of dementia.

It takes years to happen.

This is very common in these kinds of studies.

And it's due to residual confounding.

So there's like something inherently different about the populations that may be driving some of this different, right?

They were gonna get less dementia anyway.

And so maybe the shingles vaccine isn't having that big of an effect.

But I would say that having looked at all those trials and all those data, I'm fairly, you know, I'm convinced enough that there's a signal there.

There should be a randomized controlled trial.

That's happening.

But there's a number of reasons why this might be the case.

Showing 881–900 of 1,133 · page 45 of 57